Beyond intestinal soap - Bile acids in metabolic control

Nature Reviews Endocrinology

Volumn 10, Issue 8, 2014, Pages 488-498

  Kuipers, Folkert ^a   Bloks, Vincent W ^a   Groen, Albert K ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BILE ACID SEQUESTRANT; CHOLESTEROL; CHOLIC ACID; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; GLUCOSE; LIPID; SOAP; TAUROCHOLIC ACID;

BILE ACID METABOLISM; CHOLESTEROL BLOOD LEVEL; ENERGY METABOLISM; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID ABSORPTION; METABOLIC DISORDER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ALLYLAMINE; ANIMALS; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; FIBROBLAST GROWTH FACTORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84904742368     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.60     Document Type: Review

References (138)

1. Hofmann, A. F. The enterohepatic circulation of bile acids in mammals: form and functions. Front. Biosci. 14, 2584-2598 (2009).
2. Stellaard, F., Sackmann, M., Sauerbruch, T. & Paumgartner, G. Simultaneous determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates in human serum using 13C-labeled bile acids. J. Lipid Res. 25, 1313-1319 (1984).
3. Meier, P. J. & Stieger, B. Bile salt transporters. Annu. Rev. Physiol. 64, 635-661 (2002).
4. Trauner, M., Wagner, M., Fickert, P. & Zollner, G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J. Clin. Gastroenterol. 39, S111-S124 (2005).
5. Lefebvre, P., Cariou, B., Lien, F., Kuipers, F. & Staels, B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89, 147-191 (2009).
6. Brufau, G., Groen, A. K. & Kuipers, F. Reverse cholesterol transport revisited: contribution of biliary versus intestinal cholesterol excretion. Arterioscler. Thromb. Vasc. Biol. 31, 1726-1733 (2011).
7. Oude Elferink, R. P., Frijters, C. M., Paulusma, C. & Groen, A. K. Regulation of canalicular transport activities. J. Hepatol. 24 (Suppl. 1), 94-99 (1996).
8. Verkade, H. J., Vonk, R. J. & Kuipers, F. New insights into the mechanism of bile acid-induced biliary lipid secretion. Hepatology 21, 1174-1189 (1995).
9. Parks, D. J. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365-1368 (1999).
10. Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362-1365 (1999).
11. Wang, H., Chen, J., Hollister, K., Sowers, L. C. & Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3, 543-553 (1999).
12. Halilbasic, E., Claudel, T. & Trauner, M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J. Hepatol. 58, 155-168 (2013).
13. Sommer, F. & Backhed, F. The gut microbiota-masters of host development and physiology. Nat. Rev. Microbiol. 11, 227-238 (2013).
14. Backhed, F. Host responses to the human microbiome. Nutr. Rev. 70 (Suppl. 1), S14-S17 (2012).
15. Karlsson, F. H. et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498, 99-103 (2013).
16. Swann, J. R. et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc. Natl Acad. Sci. USA 108 (Suppl. 1), 4523-4530 (2011).
17. Sayin, S. I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-β-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17, 225-235 (2013).
18. Li, F. et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun. 4, 2384 (2013).
19. Hofmann, A. F. & Eckmann, L. How bile acids confer gut mucosal protection against bacteria. Proc. Natl Acad. Sci. USA 103, 4333-4334 (2006).
20. Staels, B. & Kuipers, F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 67, 1383-1392 (2007).
21. Kir, S., Kliewer, S. A. & Mangelsdorf, D. J. Roles of FGF19 in liver metabolism. Cold Spring Harb. Symp. Quant. Biol. 76, 139-144 (2011).
22. Potthoff, M. J. et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab. 13, 729-738 (2011).
23. Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621-1624 (2011).
24. Potthoff, M. J. et al. FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl Acad. Sci. USA 106, 10853-10858 (2009).
25. Maruyama, T. et al. Identification of membranetype receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714-719 (2002).
26. Kawamata, Y. et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435-9440 (2003).
27. de Aguiar Vallim, T. Q., Tarling, E. J. & Edwards, P. A. Pleiotropic roles of bile acids in metabolism. Cell Metab. 17, 657-669 (2013).
28. Pols, T. W., Noriega, L. G., Nomura, M., Auwerx, J. & Schoonjans, K. The bile acid membrane receptor TGR5: a valuable metabolic target. Dig. Dis. 29, 37-44 (2011).
29. Keely, S. J. Missing link identified: GpBAR1 is a neuronal bile acid receptor. Neurogastroenterol. Motil. 22, 711-717 (2010).
30. Keitel, V. & Haussinger, D. Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin. Res. Hepatol. Gastroenterol. 36, 412-419 (2012).
31. Thomas, C. et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10, 167-177 (2009).
32. Makishima, M. et al. Vitamin D receptor as an intestinal bile acid sensor. Science 296, 1313-1316 (2002).
33. Germain, P., Staels, B., Dacquet, C., Spedding, M. & Laudet, V. Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58, 685-704 (2006).
34. Kemper, J. K. Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications. Biochim. Biophys. Acta 1812, 842-850 (2011).
35. Fiorucci, S., Mencarelli, A., Distrutti, E., Palladino, G. & Cipriani, S. Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr. Med. Chem. 17, 139-159 (2010).
36. Zhang, Y. & Edwards, P. A. FXR signaling in metabolic disease. FEBS Lett. 582, 10-18 (2008).
37. Thomas, A. M. et al. Hepatocyte nuclear factor 4 α and farnesoid X receptor co-regulates gene transcription in mouse livers on a genome-wide scale. Pharm. Res. 30, 2188-2198 (2013).
38. Lee, J. et al. Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice. Hepatology 56, 108-117 (2012).
39. Zhang, Y., Hagedorn, C. H. & Wang, L. Role of nuclear receptor SHP in metabolism and cancer. Biochim. Biophys. Acta 1812, 893-908 (2011).
40. Zhang, Y., Kast-Woelbern, H. R. & Edwards, P. A. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J. Biol. Chem. 278, 104-110 (2003).
41. Huber, R. M. et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290, 35-43 (2002).
42. Cariou, B. et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281, 11039-11049 (2006).
43. Schote, A. B., Turner, J. D., Schiltz, J. & Muller, C. P. Nuclear receptors in human immune cells: expression and correlations. Mol. Immunol. 44, 1436-1445 (2007).
44. Rizzo, G. et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol. Pharmacol. 70, 1164-1173 (2006).
45. He, F. et al. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res. 98, 192-199 (2006).
46. Nishimura, M., Naito, S. & Yokoi, T. Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab. Pharmacokinet. 19, 135-149 (2004).
47. Bishop-Bailey, D., Walsh, D. T. & Warner, T. D. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl Acad. Sci. USA 101, 3668-3673 (2004).
48. Abdelkarim, M. et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/β-catenin pathways. J. Biol. Chem. 285, 36759-36767 (2010).
49. Prawitt, J. et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60, 1861-1871 (2011).
50. Zhang, Y. et al. Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. Mol. Endocrinol. 26, 272-280 (2012).
51. Prawitt, J., Caron, S. & Staels, B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr. Diab Rep. 11, 160-166 (2011).
52. Bjursell, M. et al. Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS ONE 8, e64721 (2013).
53. Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J. & Schoonjans, K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7, 678-693 (2008).
54. Haeusler, R. A., Pratt-Hyatt, M., Welch, C. L., Klaassen, C. D. & Accili, D. Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab. 15, 65-74 (2012).
55. Hu, X., Bonde, Y., Eggertsen, G. & Rudling, M. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. J. Intern. Med. 275, 27-38 (2014).
56. Bisschop, P. H. et al. Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans. Am. J. Clin. Nutr. 79, 570-576 (2004).
57. Jonkers, I. J. et al. Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia. J. Nutr. 136, 987-991 (2006).
58. Duran-Sandoval, D. et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53, 890-898 (2004).
59. Gineste, R. et al. Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol. Endocrinol. 22, 2433-2447 (2008).
60. Berrabah, W. et al. The glucose sensing O-GlcNacylation pathway regulates the nuclear bile acid receptor FXR. Hepatology (2013).
61. Kemper, J. K. et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 10, 392-404 (2009).
62. Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217-225 (2005).
63. Schmidt, D. R. et al. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J. Biol. Chem. 285, 14486-14494 (2010).
64. Vergnes, L, Lee, J. M., Chin, R. G., Auwerx, J. & Reue, K. Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Cell Metab. 17, 916-928 (2013).
65. Kurosu, H. et al. Tissue-specific expression of ß-Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687-26695 (2007).
66. Boulias, K. et al. Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO J. 24, 2624-2633 (2005).
67. Lundasen, T, Galman, C, Angelin, B. & Rudling, M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J. Intern. Med. 260, 530-536 (2006).
68. Jones, S. A. Physiology of FGF15/19. Adv. Exp. Med. Biol. 728, 171-182 (2012).
69. Cicione, C, Degirolamo, C. & Moschetta, A. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology 56, 2404-2411 (2012).
70. Angelin, B., Larsson, T E. & Rudling, M. Circulating fibroblast growth factors as metabolic regulators-A critical appraisal. Cell. Metab. 16, 693-705 (2012).
71. Dong, X. et al. Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J. Clin. Invest. 116, 101-114 (2006).
72. Fang, Q. et al. Serum fibroblast growth factor 19 levels are decreased in Chinese subjects with mpaired fasting glucose and inversely associated with fasting plasma glucose levels. Diabetes Care 36, 2810-2814 (2013).
73. Barutcuoglu, B. et al. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann. Clin. Lab. Sci. 41, 390-396 (2011).
74. Keitel, V., Ullmer, C. & Haussinger, D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol. Chem. 391, 785-789 (2010).
75. Pellicciari, R. et al. Discovery of 6a-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52, 7958-7961 (2009).
76. Watanabe, M. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484-489 (2006).
77. Watanabe, M. et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J. Biol. Chem. 286, 26913-26920 (2011).
78. Watanabe, M. et al. Bile acid binding resin improves metabolic control through the induction of energy expenditure. PLoS ONE 7, e38286 (2012).
79. Maruyama, T. et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J. Endocrinol. 191, 197-205 (2006).
80. Sato, H. et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem. Biophys. Res. Commun. 362, 793-798 (2007).
81. Svensson, P. A. et al. The TGR5 gene is expressed in human subcutaneous adipose tissue and is associated with obesity, weight loss and resting metabolic rate. Biochem. Biophys. Res. Commun. 433, 563-566 (2013).
82. Patti, M. E. et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17, 1671-1677 (2009).
83. Kohli, R. et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J. Clin. Endocrinol. Metab. 98, E708-E712 (2013).
84. Steinert, R. E. et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity (Silver Spring) 21, E660-E668 (2013).
85. Brufau, G. et al. Plasma bile acids are not associated with energy metabolism in humans. Nutr. Metab. (Lond.) 7, 73 (2010).
86. Ockenga, J. et al. Plasma bile acids are associated with energy expenditure and thyroid function in humans. J. Clin. Endocrinol. Metab. 97, 535-542 (2012).
87. Jansen, P. L. et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig. Dis. 29, 48-51 (2011).
88. Gerhard, G. S. et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care 36, 1859-1864 (2013).
89. Pournaras, D. J. et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 153, 3613-3619 (2012).
90. Potthoff, M. J., Kliewer, S. A. & Mangelsdorf, D. J. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 26, 312-324 (2012).
91. Morton, G. J. et al. FGF19 action in the brain induces insulin-independent glucose lowering. J. Clin. Invest. 123, 4799-4808 (2013).
92. Holst, J. J. & McGill, M. A. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants. Clin. Drug Investig. 32, 1-14 (2012).
93. Holst, J. J. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr. Opin. Pharmacol. 13, 983-988 (2013).
94. Shah, M. et al. Contribution of endogenous glucagon-like peptide-1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes 63, 483-493 (2014).
95. Claudel, T., Sturm, E., Kuipers, F. & Staels, B. The farnesoid X receptor: a novel drug target? Expert Opin. Investig. Drugs 13, 1135-1148 (2004).
96. Fiorucci, S., Mencarelli, A., Distrutti, E. & Zampella, A. Farnesoid X receptor: from medicinal chemistry to clinical applications. Future Med. Chem. 4, 877-891 (2012).
97. Porez, G., Prawitt, J., Gross, B. & Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J. Lipid Res. 53, 1723-1737 (2012).
98. Schaap, F. G., Trauner, M. & Jansen, P. L. Bile acid receptors as targets for drug development. Nat. Rev. Gastroenterol. Hepatol. 11, 55-67 (2014).
99. Halilbasic, E., Baghdasaryan, A. & Trauner, M. Nuclear receptors as drug targets in cholestatic liver diseases. Clin. Liver Dis. 17, 161-189 (2013).
100. Trauner, M. et al. Targeting nuclear bile acid receptors for liver disease. Dig. Dis. 29, 98-102 (2011).
101. Chiang, J. Y. Bile acid metabolism and signaling. Compr. Physiol. 3, 1191-1212 (2013).
102. Li, T. & Chiang, J. Y. Nuclear receptors in bile acid metabolism. Drug Metab. Rev. 45, 145-155 (2013).
103. Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574-82.e1 (2013).
104. Reasner, C. A. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J. Cardiovasc. Pharmacol. 52, 136-144 (2008).
105. Robinson, J. G., Wang, S., Smith, B. J. & Jacobson, T. A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J. Am. Coll. Cardiol. 53, 316-322 (2009).
106. Garg, A. & Grundy, S. M. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann. Intern. Med. 121, 416-422 (1994).
107. Bays, H. E., Goldberg, R. B., Truitt, K. E. & Jones, M. R. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch. Intern. Med. 168, 1975-1983 (2008).
108. Fonseca, V. A., Rosenstock, J., Wang, A. C., Truitt, K. E. & Jones, M. R. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31, 1479-1484 (2008).
109. Goldberg, R. B., Fonseca, V. A., Truitt, K. E. & Jones, M. R. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch. Intern. Med. 168, 1531-1540 (2008).
110. Rosenstock, J. et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr. Pract. 16, 629-640 (2010).
111. Schwartz, S. L. et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab. Syndr. Relat. Disord. 8, 179-188 (2010).
112. Rosenson, R. S., Abby, S. L. & Jones, M. R. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis 204, 342-344 (2009).
113. Zieve, F. J., Kalin, M. F., Schwartz, S. L., Jones, M. R. & Bailey, W. L. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin. Ther. 29, 74-83 (2007).
114. Ooi, C. P. & Loke, S. C. Colesevelam for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, Issue 12. Art. No.: CD009361 http://dx.doi.org/10.1002/14651858.CD009361.pub2.
115. Brufau, G. et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 52, 1455-1464 (2010).
116. Suhre, K. et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 5, e13953 (2010).
117. Bennion, L. J. & Grundy, S. M. Effects of diabetes mellitus on cholesterol metabolism in man. N. Engl. J. Med. 296, 1365-1371 (1977).
118. de Leon, M. P., Ferenderes, R. & Carulli, N. Bile lipid composition and bile acid pool size in diabetes. Am. J. Dig. Dis. 23, 710-716 (1978).
119. Abrams, J. J., Ginsberg, H. & Grundy, S. M. Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus. Diabetes 31, 903-910 (1982).
120. Haber, G. B. & Heaton, K. W. Lipid composition of bile in diabetics and obesity-matched controls. Gut 20, 518-522 (1979).
121. Andersen, E., Karlaganis, G. & Sjovall, J. Altered bile acid profiles in duodenal bile and urine in diabetic subjects. Eur. J. Clin. Invest. 18, 166-172 (1988).
122. Beysen, C. et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 55, 432-442 (2012).
123. Shang, Q., Saumoy, M., Holst, J. J., Salen, G. & Xu, G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G419-G424 (2010).
124. Smushkin, G. et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes 62, 1094-1101 (2013).
125. Herrema, H. et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor-and liver X receptor α-controlled metabolic pathways in mice. Hepatology 51, 806-816 (2010).
126. Meissner, M. et al. Bile acid sequestration reduces plasma glucose levels in db/db mice by increasing its metabolic clearance rate. PLoS ONE 6, e24564 (2011).
127. Hofmann, A. F. Bile acid sequestrants improve glycemic control in type 2 diabetes: a proposed mechanism implicating glucagon-like peptide 1 release. Hepatology 53, 1784 (2011).
128. Potthoff, M. J. et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G371-G380 (2013).
129. Wu, T. et al. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes. Metab. 15, 474-477 (2013).
130. Lundasen, T. et al. Inhibition of intestinal bile acid transporter Slc10a2 improves triglyceride metabolism and normalizes elevated plasma glucose levels in mice. PLoS ONE 7, e37787 (2012).
131. Kharitonenkov, A. et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627-1635 (2005).
132. Coskun, T. et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149, 6018-6027 (2008).
133. Xu, J. et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250-259 (2009).
134. Brestoff, J. R. & Artis, D. Commensal bacteria at the interface of host metabolism and the immune system. Nat. Immunol. 14, 676-684 (2013).
135. Papacleovoulou, G. et al. Maternal cholestasis during pregnancy programs metabolic disease in offspring. J. Clin. Invest. 123, 3172-3181 (2013).
136. Bochkis, I. M., Shin, S. & Kaestner, K. H. Bile acid-induced inflammatory signaling in mice lacking Foxa2 in the liver leads to activation of mTOR and age-onset obesity. Mol. Metab. 2, 447-456 (2013).
137. Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137-174 (2003).
138. Russell, D. W. Fifty years of advances in bile acid synthesis and metabolism. J. Lipid Res. 50 (Suppl.), S120-S125 (2009).